Cited by 1,521HIV-related health complications and treatmentsHIV/AIDS drug development and treatmentLipoproteins and Cardiovascular Health

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

Open access

The DAD Study Group·2007·New England Journal of Medicine

DOI 10.1056/nejmoa062744

Open this paper in CoChat — free account

Abstract

BACKGROUND: We have previously demonstrated an association between combination antiretroviral therapy and the risk of myocardial infarction. It is not clear whether this association differs according to the class of antiretroviral drugs. We conducted a study to investigate the association of cumulative exposure to protease inhibitors and nonnucleoside reverse-transcriptase inhibitors with the risk of myocardial infarction. METHODS: We analyzed data collected through February 2005 from our prospective observational study of 23,437 patients infected with the human immunodeficiency virus. The incidence rates of myocardial infarction during the follow-up period were calculated, and the associations between myocardial infarction and exposure to protease inhibitors or nonnucleoside reverse-transcriptase inhibitors were determined. RESULTS: Three hundred forty-five patients had a myocardial infarction during 94,469 person-years of observation. The incidence of myocardial infarction increased from 1.53 per 1000 person-years in those not exposed to protease inhibitors to 6.01 per 1000 person-years in those exposed to protease inhibitors for more than 6 years. After adjustment for exposure to the other drug class and established cardiovascular risk factors (excluding lipid levels), the relative rate of myocardial infarction per year of protease-inhibitor exposure was 1.16 (95% confidence interval [CI], 1.10 to 1.23), whereas the relative rate per year of exposure to nonnucleoside reverse-transcriptase inhibitors was 1.05 (95% CI, 0.98 to 1.13). Adjustment for serum lipid levels further reduced the effect of exposure to each drug class to 1.10 (95% CI, 1.04 to 1.18) and 1.00 (95% CI, 0.93 to 1.09), respectively. CONCLUSIONS: Increased exposure to protease inhibitors is associated with an increased risk of myocardial infarction, which is partly explained by dyslipidemia. We found no evidence of such an association for nonnucleoside reverse-transcriptase inhibitors; however, the number of person-years of observation for exposure to this class of drug was less than that for exposure to protease inhibitors.

Integrity signals

Registry

Crossref · 10.1056/nejmoa062744

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,393
Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.-M., & Pająk, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,260
CD4+ Count–Guided Interruption of Antiretroviral Treatment
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062360 · Cited by 2,250
Self-citation
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
El-Sadr, W. M., & The Data Collection On Adverse Events Of Anti-HIV Drugs (DAD) Study Group (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,677
Self-citation
Changing patterns of mortality across Europe in patients infected with HIV-1
Mocroft, A., Vella, S., Benfield, T., Chiesi, A., Miller, V., Gargalianos, P., Monforte, A. D., Yust, I., Bruun, J., Phillips, A. N., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03201-2 · Cited by 1,269
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
Friis‐Møller, N., Weber, R. K., Reiss, P., Thiébaut, R., Kirk, O., Monforte, A. D., Pradier, C., Morfeldt, L., Mateu, S., Law, M. G., et al. (2003) · AIDS · doi:10.1097/00002030-200305230-00010 · Cited by 1,076
Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
Staszewski, S., Morales-Ramirez, J. O., Tashima, K. T., Rachlis, A., Skiest, D. J., Stanford, J., Stryker, R., Johnson, P. C., Labriola, D., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B. J., Battegay, M., Vernazza, P., Sudre, P., Flepp, M., Furrer, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01122-8 · Cited by 906
Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
Grünfeld, C., Pang, M., Doerrler, W. T., Shigenaga, J. K., Jensen, P., & Feingold, K. R. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.74.5.1373735 · Cited by 845
Impact of HIV infection and HAART on serum lipids in men
Riddler, S. A. (2003) · JAMA · doi:10.1001/jama.289.22.2978 · Cited by 624

Flagged first, then by citations

Show all 26 references

Research works printed but not linked: 3

10.1210/jc.74.5.1045 · DOI
Phillips AN, Carr A, Neuhaus J, et al. Interruption of ART and risk of cardiovascular disease: findings from SMART. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 26, 2007. abstract. (Accessed March 29, 2007, athttp://www.retroconference.org/2007/abstracts/28863.htm.)
Sabin C, Morfeldt L, Friis-Møller N, et al. Changes over time in antiretroviral therapy (ART) use and risk factors for cardiovascular disease (CVD) in the D:A:D study. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 25, 2005. abstract. (Accessed March 29, 2007, athttp://www.retroconference.org/2005/cd/abstracts/25243.htm.)

Sorted by citations

Items 601–700 of 999

HIV and Global Cardiovascular Health
Wagle, A. A., Goerlich, E., Post, W. S., Woldu, B., Wu, K. C., & Hays, A. G. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01741-1 · Cited by 24
Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy
Begovać, J., Dragović, G., Višković, K., Kušić, J., Mihanović, M. P., Lukas, D., & Jevtović, D. (2015) · Croatian Medical Journal · doi:10.3325/cmj.2015.56.14 · Cited by 23
Associação dos biomarcadores com aterosclerose e risco para doença coronariana em portadores de HIV
Falcão, M. D. C. B. D. A., Zírpoli, J. C., de Albuquerque, V. M., Filho, B. M., de Araújo, N. A. M., Falcão, C. A., Miranda-Filho, D. D. B., Ximenes, R. A. D. A., de Albuquerque, M. D. F. P. M., & Lacerda, H. R. (2012) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2012005000093 · Cited by 23
Evaluating competing adverse and beneficial outcomes using a mixture model
Lau, B. M., Cole, S. R., Moore, R. D., & Gange, S. J. (2008) · Statistics in Medicine · doi:10.1002/sim.3293 · Cited by 23
Circulating Heat Shock Protein 60 Levels Are Elevated in HIV Patients and Are Reduced by Anti-Retroviral Therapy
Anraku, I., Rajasuriar, R., Dobbin, C. A., Brown, R., Lewin, S. R., & Suhrbier, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045291 · Cited by 23
Arterial stiffness and carotid intima-media thickness in HIV infected patients.
Papita, A., Albu, A., Fodor, D., Itu, C., & Cârstina, D. (2011) · PubMed · Cited by 23
Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review
Souza, S. J., Luzia, L. A., dos Santos, S. D. S., & Rondó, P. H. D. C. (2013) · Revista da Associação Médica Brasileira (English Edition) · doi:10.1016/s2255-4823(13)70454-5 · Cited by 23
Hypertension and Isolated Office Hypertension in HIV-Infected Patients Determined By Ambulatory Blood Pressure Monitoring: Prevalence and Risk Factors
Bernardino, J. I., Mora-Rillo, M., Zamora, F. X., Arribas-Arribas, B., Montes, M., Pareja, J. F. P., José, B. S., Peña, J. M., & Arribas, J. R. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182267406 · Cited by 23
Elevated homocysteine levels in human immunodeficiency virus-infected patients under antiretroviral therapy: A meta-analysis
Deminice, R. (2015) · World Journal of Virology · doi:10.5501/wjv.v4.i2.147 · Cited by 24
Coronary heart disease in people infected with HIV
Malvestutto, C., & Aberg, J. A. (2010) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.77a.09119 · Cited by 22
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment
Vandekerckhove, L., Verhofstede, C., Demecheleer, E., Wit, S. D., Florence, É., Fransen, K., Moutschen, M. P., Mostmans, W., Kabeya, K., Mackie, N., et al. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq458 · Cited by 22
Associations between antiretroviral use and subclinical coronary atherosclerosis
Thomas, G. P., Li, X., Post, W. S., Jacobson, L. P., Witt, M. D., Brown, T. T., Kingsley, L., Phair, J., & Palella, F. J. (2016) · AIDS · doi:10.1097/qad.0000000000001220 · Cited by 22
Comparison of the ACC/AHA and Framingham algorithms to assess cardiovascular risk in HIV-infected patients
Neto, L. F. D. S. P., Dias, F. R., Bressan, F. F., & Santos, C. R. O. (2017) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2017.06.007 · Cited by 22
Etiology and pathophysiology of heart failure in people with HIV
Choi, H., Dey, A. K., Sharma, G., Bhoite, R. R., Burkholder, G., Fedson, S., & Jneid, H. M. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10048-8 · Cited by 22
Human Immunodeficiency Virus Infection and Variation in Heart Failure Risk by Age, Sex, and Ethnicity: The HIV HEART Study
Go, A. S., Reynolds, K., Avula, H. R., Towner, W. J., Hechter, R. C., Horberg, M. A., Vupputuri, S. X., Leong, T. K., Leyden, W. A., Harrison, T. N., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.10.004 · Cited by 22
HIV and coronary artery calcium score: comparison of the Hawaii Aging with HIV Cardiovascular Study and Multi-Ethnic Study of Atherosclerosis (MESA) cohorts
Chow, D. C., Young, R. L., Valcour, N., Kronmal, R. A., Lum, C. J., Parikh, N. I., Tracy, R. P., Budoff, M. J., & Shikuma, C. M. (2015) · HIV Clinical Trials · doi:10.1179/1528433614z.0000000016 · Cited by 23
Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients
Gianotti, N., Visco, F., Galli, L., Barda, B., Piatti, P. M., Salpietro, S., Bigoloni, A., Vinci, C., Nozza, S., Gallotta, G., et al. (2010) · HIV Medicine · doi:10.1111/j.1468-1293.2010.00860.x · Cited by 22
Changes in the clinical epidemiology of HIV infection in the United States: Implications for the clinician
Buchacz, K. A., Rangel, M., Blacher, R. J., & Brooks, J. T. (2008) · Current Infectious Disease Reports · doi:10.1007/s11908-009-0011-9 · Cited by 22
Microvascular Endothelial Dysfunction and Enhanced Thromboxane and Endothelial Contractility in Patients with HIV
Wang, D. (2013) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.1000267 · Cited by 22
Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients
Fitch, K. V., & Grinspoon, S. K. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.012120 · Cited by 22
Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation
Dubé, M. P., Komarow, L., Fichtenbaum, C. J., Cadden, J. J., Overton, E. T., Hodis, H. N., Currier, J. S., & Stein, J. H. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ385 · Cited by 22
Longitudinal assessment of cardiac diastolic function in HIV-infected patients
Blaylock, J. M., Byers, D. K., Gibbs, B. T., Nayak, G., Ferguson, M. A., Tribble, D. R., Porter, C. K., & Decker, C. F. (2012) · International Journal of STD & AIDS · doi:10.1258/ijsa.2011.011099 · Cited by 22
Ezetimibe Combined with Low-Dose Statin Effectively Lowers LDL in Protease Inhibitor Treated Patients
van den Berg-Wolf, M., Klibanov, O. M., Gaughan, J. P., & Tedaldi, E. (2008) · AIDS Patient Care and STDs · doi:10.1089/apc.2007.0206 · Cited by 22
Smoking Cessation Among Women with and at Risk for HIV: Are They Quitting?
Goldberg, D. N., Weber, K. M., Orsi, J. M., Hessol, N. A., DʼSouza, G., Watts, D. H., Schwartz, R. M., Liu, C., Glesby, M. J., Burian, P., et al. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-009-1150-2 · Cited by 23
Sex Differences in the Treatment of HIV
Cohn, J., Ake, J. A., Moorhouse, M. A., & Godfrey, C. C. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00499-x · Cited by 22
Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment–Experienced People Living With Human Immunodeficiency Virus
Greenberg, L., Ryom, L., Neesgaard, B., Wandeler, G., Staub, T., Gisinger, M., Skoll, M., Günthard, H. F., Scherrer, A., Mussini, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1878 · Cited by 21
Anti-inflammatory effect of rosuvastatin in patients with HIV infection: An FDG-PET pilot study
Boczar, K. E., Faller, E., Zeng, W., Wang, J., Small, G. R., Corrales‐Medina, V., deKemp, R. A., Ward, N. C., Beanlands, R. S., MacPherson, P. A., et al. (2021) · Journal of Nuclear Cardiology · doi:10.1007/s12350-021-02830-4 · Cited by 21
Dyslipidemia in HIV Infected Children Receiving Highly Active Antiretroviral Therapy
Mandal, A., Mukherjee, A., Ramakrishnan, L., Kabra, S. K., & Lodha, R. (2015) · The Indian Journal of Pediatrics · doi:10.1007/s12098-015-1859-3 · Cited by 21
The Relationship Between Vitamin D Status and HIV-related Complications in HIV-infected Children and Young Adults
Eckard, A. R., Tangpricha, V., Seydafkan, S., O’Riordan, M. A., Storer, N. J., Labbato, D. E., & McComsey, G. A. (2013) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e318286c793 · Cited by 21
Efavirenz induces interactions between leucocytes and endothelium through the activation of Mac-1 and gp150,95
Orden, S., Pablo, C. D., Ríos‐Navarro, C., Martínez-Cuesta, M. Á., Peris, J., Barrachina, M. D., Esplugues, J. V., & Álvarez, Á. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt468 · Cited by 21
HIV INFECTION, ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR RISK
Donati, K. D. G., Cauda, R., & Iacoviello, L. (2010) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2010.034 · Cited by 21
Thirty years of the human immunodeficiency virus epidemic and beyond
Younai, F. (2013) · International Journal of Oral Science · doi:10.1038/ijos.2013.76 · Cited by 16
Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy
Kaplan‐Lewis, E., Aberg, J. A., & Lee, M.-K. (2016) · Current HIV/AIDS Reports · doi:10.1007/s11904-016-0331-y · Cited by 21
Treated HIV Infection and Progression of Carotid Atherosclerosis in Rural Uganda: A Prospective Observational Cohort Study
Siedner, M. J., Bibangambah, P., Kim, J., Lankowski, A. J., Chang, J. L., Yang, I. T., Kwon, D. S., North, C. M., Triant, V. A., Longenecker, C. T., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019994 · Cited by 21
Endocrine, metabolic, and immunologic components of HIV infection
Norbiato, G. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06620.x · Cited by 21
Lipodystrophy in children and adolescents with acquired immunodeficiency syndrome and its relationship with the antiretroviral therapy employed
Sarni, R. O. S., de Souza, F. I. S., Battistini, T. R. B., Pitta, T. S., Fernandes, A. P., Tardini, P. C., Fonseca, F. L. A., dos Santos, V. P., & Lopez, F. A. (2009) · Jornal de Pediatria · doi:10.2223/jped.1910 · Cited by 21
Sex- and Poverty-Specific Patterns in Cardiovascular Disease Mortality Associated With Human Immunodeficiency Virus, New York City, 2007–2017
Hanna, D. B., Ramaswamy, C., Kaplan, R. C., Kizer, J. R., Daskalakis, D., Anastos, K., & Braunstein, S. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz852 · Cited by 20
Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV
Greenberg, L., Ryom, L., Bąkowska, E., Wit, F. W. N. M., Bucher, H. C., Braun, D. L., Phillips, A. N., Sabin, C. A., Monforte, A. D., Zangerle, R., et al. (2023) · Cancers · doi:10.3390/cancers15143640 · Cited by 20
Efficacy and Safety of Atazanavir-Ritonavir Plus Abacavir-Lamivudine or Tenofovir-Emtricitabine in Patients with Hyperlipidaemia Switched from a Stable Protease Inhibitor-Based Regimen Including One Thymidine Analogue
Calza, L., Manfredi, R., Colangeli, V., Pocaterra, D., Rosseti, N., Pavoni, M., & Chiodo, F. (2009) · AIDS Patient Care and STDs · doi:10.1089/apc.2009.0039 · Cited by 20
Impaired diastolic function in naïve untreated human immunodeficiency virus infected patients
Oliviero, U. (2010) · World Journal of Cardiology · doi:10.4330/wjc.v2.i4.98 · Cited by 20
Rate and Predictors of Carotid Artery Intima Media Thickness Progression in Antiretroviral-Naive HIV-Infected and Uninfected Adults: A 48-Week Matched Prospective Cohort Study
Hileman, C. O., Carman, T. L., Longenecker, C. T., Labbato, D. E., Storer, N. J., White, C. A., & McComsey, G. A. (2013) · Antiviral Therapy · doi:10.3851/imp2651 · Cited by 20
Abacavir use and risk of recurrent myocardial infarction
Sabin, C. A., Ryom, L., Monforte, A. D., Hatleberg, C. I., Pradier, C., El-Sadr, W. M., Kirk, O., Weber, R. K., Phillips, A. N., Mocroft, A., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001666 · Cited by 20
Heart health in the age of highly active antiretroviral therapy
Belkin, M. N., & Uriel, N. Y. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000513 · Cited by 20
Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study
Dai, L., Liu, A., Zhang, H., Wu, H., Zhang, T., Su, B., Shao, Y., Li, J., Ye, J., Scott, S. R., et al. (2019) · Current HIV Research · doi:10.2174/1570162x17666191025115508 · Cited by 20
Coronary Artery Disease in Patients with HIV Infection: An Update
Patel, A., & Budoff, M. J. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00451-9 · Cited by 21
Pathogenesis of cardiovascular disease in HIV infection
Carr, A. D. (2008) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3282fb7be0 · Cited by 20
A meta‐analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir‐boosted protease inhibitor maintenance therapy in HIV‐infected adults with established virological suppression after induction
Baril, J.-G., Conway, B., Giguère, P., Ferko, N. C., Hollmann, S., & Angel, J. B. (2013) · HIV Medicine · doi:10.1111/hiv.12118 · Cited by 19
Treatment-for-prevention
Lockman, S., & Sax, P. E. (2012) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32834fcf6b · Cited by 19
Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review
Chow, D. C., Shikuma, C. M., Ritchings, C., Guo, M., & Rosenblatt, L. C. (2016) · Infectious Diseases and Therapy · doi:10.1007/s40121-016-0132-z · Cited by 19
Risk factors and outcomes of HIV-associated stroke in Zambia
Zimba, S., Nutakki, A., Chishimba, L., Chomba, M., Bahouth, M. N., Gottesman, R. F., & Saylor, D. R. (2021) · AIDS · doi:10.1097/qad.0000000000002999 · Cited by 19
QT Dispersion in HIV‐Infected Patients Receiving Combined Antiretroviral Therapy
Wongcharoen, W., Suaklin, S., Tantisirivit, N., Phrommintikul, A., & Chattipakorn, N. (2014) · Annals of Noninvasive Electrocardiology · doi:10.1111/anec.12162 · Cited by 19
Cardiovascular complications in the acquired immunodeficiency syndrome
Bárbaro, G., & da Silva, É. F. R. (2009) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302009000500031 · Cited by 19
NeuroAIDS in the Asia Pacific Region
Wright, E., Nunn, M. F., Joseph, J., Robertson, K., Lal, L., & Brew, B. J. (2008) · Journal of NeuroVirology · doi:10.1080/13550280802235932 · Cited by 19
Role of intestinal myofibroblasts in HIV-associated intestinal collagen deposition and immune reconstitution following combination antiretroviral therapy
Asmuth, D. M., Pinchuk, I. V., Wu, J., Vargas, G., Chen, X., Mann, S. K., Albanese, A. P., Ma, Z.-M., Saroufeem, R. M. G., MELCHER, G. P., et al. (2015) · AIDS · doi:10.1097/qad.0000000000000636 · Cited by 21
Cardiac Abnormalities in HIV-Positive Patients
Jain, N., Reddy, D. H., Verma, S. P., Khanna, R., Vaish, A. K., Usman, K., Tripathi, A. K., Singh, A., Mehrotra, S., & Gupta, A. (2012) · Journal of the International Association of Providers of AIDS Care (JIAPAC) · doi:10.1177/1545109712456740 · Cited by 19
Hot Immunological Topics in HIV Infection
Pineda, J. A., Alcamı́, J., Blanco, J. R., Blanco, J., & Boix, V. (2011) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.1000118 · Cited by 18
Micronutrient concentrations and subclinical atherosclerosis in adults with HIV
Falcone, E. L., Mangili, A., Tang, A., Jones, C. Y., Woods, M. N., Polak, J. F., & WANKE, C. A. (2010) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28816 · Cited by 19
The prevalence of airway obstruction among Japanese HIV-positive male patients compared with general population; a case–control study of single center analysis
Nakamura, H., Tateyama, M., Tasato, D., Haranaga, S., Ishimine, T., Higa, F., Kaneshima, H., & Fujita, J. (2014) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2014.02.001 · Cited by 19
Intima-Media Thickness in the Carotid and Femoral Arteries for Detection of Arteriosclerosis in Human Immunodeficiency Virus-Positive Individuals
Godoi, E. T. A. M., Brandt, C. T., Lacerda, H. R., Godoi, J. T. A. M., de Oliveira, D. C., Costa, G. F. A. S., dos Santos, G. G., Leite, K. M. E., Godoi, J. T. A. M., & Vasconcelos, A. F. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160197 · Cited by 19
Mortal allies
Mayne, E. S., & George, J. A. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000342 · Cited by 19
Severe infection increases cardiovascular risk among HIV-infected individuals
Mesquita, E. C., Coelho, L. E., Amancio, R. T., Veloso, V. G., Grinsztejn, B. G. J., Luz, P. M., & Bozza, F. A. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-3894-6 · Cited by 20
Estimated risk of cardiovascular disease among the HIV-positive patients aged 40 years or older in Taiwan
Wu, P., Chen, M.-Y., Sheng, W., Hsieh, S., Chuang, Y., Cheng, A., Pan, S., Wu, U., Chang, H., Luo, Y., et al. (2019) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2019.03.006 · Cited by 21
The Opioid Epidemic: Impact on Inflammation and Cardiovascular Disease Risk in HIV
Hileman, C. O., & McComsey, G. A. (2019) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00463-4 · Cited by 17
Association of non-HDL cholesterol with subclinical atherosclerosis in HIV-positive patients
Badiou, S., Thiébaut, R., Aurillac-Lavignolle, V., Dabis, F., Laporte, F., Cristol, J., & Mercié, P. (2008) · Journal of Infection · doi:10.1016/j.jinf.2008.05.007 · Cited by 19
Safety and Efficacy of Simvastatin for the Treatment of Dyslipidemia in Human Immunodeficiency Virus‐Infected Patients Receiving Efavirenz‐Based Highly Active Antiretroviral Therapy
Rahman, A. P., Eaton, S. A., Nguyen, S., Bain, A. M., Payne, K. D., Bedimo, R., & Busti, A. J. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.7.913 · Cited by 19
Arterial hypertension and cardiovascular risk in HIV-infected patients
Calò, L. A., Caielli, P., Maiolino, G., & Rossi, G. P. (2013) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e3283621f01 · Cited by 19
Cardiovascular Disease Risk Factors in HIV-Infected Women After Initiation of Lopinavir/Ritonavir- and Nevirapine-Based Antiretroviral Therapy in Sub-Saharan Africa
Shaffer, D., Hughes, M. D., Sawe, F., Bao, Y., Moses, A., Hogg, E., Lockman, S., & Currier, J. S. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000131 · Cited by 18
Virological efficacy of abacavir: systematic review and meta-analysis
Cruciani, M., Mengoli, C., Malena, M., Serpelloni, G., Parisi, S. G., Moyle, G. J., & Bosco, O. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku279 · Cited by 18
Does Antiretroviral Therapy Increase or Decrease the Risk of Cardiovascular Disease?
Fichtenbaum, C. J. (2010) · Current HIV/AIDS Reports · doi:10.1007/s11904-010-0045-5 · Cited by 18
Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity: A Substudy of the Strategic Timing of AntiRetroviral Treatment (START) Trial
Baker, J. V., Hullsiek, K. H., Engen, N. W., Nelson, R., Chetchotisakd, P., Gerstoft, J., Jessen, H. K., Losso, M. H., Markowitz, N. P., Munderi, P., et al. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw213 · Cited by 18
Increased cardiovascular risk in HIV infection: drugs, virus and immunity
Murphy, R. L., & Costagliola, D. G. (2008) · AIDS · doi:10.1097/qad.0b013e328306a6db · Cited by 18
Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations
Cruciani, M., & Malena, M. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s65199 · Cited by 18
Clinical Inertia in the Management of Low‐Density Lipoprotein Abnormalities in an HIV Clinic
Willig, J. H., Jackson, D. A., Westfall, A. O., Allison, J. J., Chang, P., Raper, J. L., Saag, M. S., & Mugavero, M. J. (2008) · Clinical Infectious Diseases · doi:10.1086/533466 · Cited by 18
Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection
Fichtenbaum, C. J. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0153-9 · Cited by 18
Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study
Masiá, M., Martínez, E., Padilla, S., Gatell, J., & Gutiérrez, F. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks412 · Cited by 18
Ritonavir-Induced Lipoatrophy and Dyslipidaemia is Reversed by the Anti-Inflammatory Drug Leflunomide in a Ppar-Γ-Dependent Manner
Mencarelli, A., Francisci, D., Renga, B., D’Amore, C., Cipriani, S., Basile, F., Schiaroli, E., Baldelli, F., & Fiorucci, S. (2012) · Antiviral Therapy · doi:10.3851/imp2039 · Cited by 18
The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro
Loelius, S. G., Lannan, K. L., Blumberg, N., Phipps, R. P., & Spinelli, S. L. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.07.003 · Cited by 18
Muertes por enfermedades no asociadas directamente con el sida en pacientes con infección por el VIH: un estudio de 14 años (1998-2011)
López, C., Masiá, M., Padilla, S., Aquilino, A., Bas, C., & Gutiérrez, F. (2015) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2015.04.010 · Cited by 18
Lipoprotein levels and cardiovascular risk in HIV-infected and uninfected Rwandan women
Anastos, K., Ndamage, F., Lu, D., Cohen, M. H., Shi, Q., Lazar, J., Bigirimana, V., & Mutimura, E. (2010) · AIDS Research and Therapy · doi:10.1186/1742-6405-7-34 · Cited by 18
Vitamin D Deficiency in HIV-Infected Women on Antiretroviral Therapy Living in the Tropics
Conrado, T., Miranda-Filho, D. D. B., Ximenes, R. A. D. A., de Albuquerque, M. D. F. P. M., Lacerda, H. R., Ramos, R. C. F., de Araújo, P. S. R., Montarroyos, U. R., & Bandeira, F. A. F. (2011) · Journal of the International Association of Physicians in AIDS Care · doi:10.1177/1545109711399657 · Cited by 18
Antiretroviral Therapy for Human Immunodeficiency Virus Infection
Tsibris, A. M. N., & Hirsch, M. (2015) · Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases · doi:10.1016/b978-1-4557-4801-3.00130-2 · Cited by 18
Hypopituitarism and HIV-infection: a new comorbidity in the HAART era?
Zirilli, L., Orlando, G., Diazzi, C., Squillace, N., Carani, C., Guaraldi, G., & Rochira, V. (2008) · PubMed · Cited by 18
Effect of vitamin A and vitamin C supplementation on oxidative stress in HIV and HIV-TB co-infection at Lagos University Teaching Hospital (LUTH) Nigeria
Makinde, O., Rotimi, K., Ikumawoyi, V. O., Adeyemo, T. A., & Olayemi, S. O. (2017) · African Health Sciences · doi:10.4314/ahs.v17i2.3 · Cited by 18
Trends in Nonlipid Cardiovascular Disease Risk Factor Management in the Women's Interagency HIV Study and Association with Adherence to Antiretroviral Therapy
Hanna, D. B., Jung, M., Xue, X., Anastos, K., Cocohoba, J. M., Cohen, M. H., Golub, E. T., Hessol, N. A., Levine, A. M., Wilson, T. E., et al. (2016) · AIDS Patient Care and STDs · doi:10.1089/apc.2016.0143 · Cited by 17
Relationship Between HIV Infection, Antiretroviral Therapy, Inflammatory Markers, and Cerebrovascular Endothelial Function Among Adults in Urban China
Chow, F. C., Li, Y., Hu, Y., Chan, J., Wang, H., Xu, W., Price, R. W., Sorond, F. A., & Li, T. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001254 · Cited by 17
Prelamin A and ZMPSTE24 in premature and physiological aging
Worman, H. J., & Michaelis, S. (2023) · Nucleus · doi:10.1080/19491034.2023.2270345 · Cited by 18
Coronary Artery Disease in Patients with HIV Infection
Patel, A., & Budoff, M. J. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0105-8 · Cited by 17
Cardiovascular Complications of HIV-Associated Immune Dysfunction
Zaaqoq, A. M., Khasawneh, F. A., & Smalligan, R. D. (2015) · Cardiology Research and Practice · doi:10.1155/2015/302638 · Cited by 21
Regulation of oxidative stress in response to acute aerobic and resistance exercise in HIV-infected subjects: a case–control study
Deresz, L. F., Sprinz, E., Kramer, A. S., Cunha, G. D. S., Reischak-Oliveira, Á., SPORLEDER, H. ‐., de Freitas, D. R. J., Lazzarotto, A. R., & Lago, P. D. (2010) · AIDS Care · doi:10.1080/09540121003758549 · Cited by 17
HIV-1 Infection and the Aging of the Immune System: Facts, Similarities and Perspectives
Biasi, S. D., Pinti, M., Nasi, M., Gibellini, L., Bertoncelli, L., Manzini, S., Mussini, C., & Cossarizza, A. (2011) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2011.06.001 · Cited by 17
Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia
Lu, C.-L., Lin, Y., Wong, W.-W., Lin, H.-H., Ho, M., Wang, N., Hsieh, S., Sheng, W., Hung, C., & Chen, M.-Y. (2011) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2010.08.003 · Cited by 17
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
for the SUPPORT Study Team, Kumar, P. N., DeJesus, E., Huhn, G. D., Sloan, L. M., Small, C. B., Edelstein, H. E., Felizarta, F., Hao, R. M., Ross, L., et al. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-269 · Cited by 17
Changes of metabolic and inflammatory markers in HIV infection: glucose, lipids, serum Hs-CRP and myeloperoxidase
Borato, D. C. K., Parabocz, G. C., Ribas, S. R. W., Kalva‐Filho, C. A., Borba, L. M., Ito, C. A. S., Bail, L., dos Santos, F. A., & Vellosa, J. C. R. (2012) · Metabolism · doi:10.1016/j.metabol.2012.03.003 · Cited by 17
Therapeutic Interventions to Enhance Apolipoprotein A-I-Mediated Cardioprotection
Haas, M. J., & Mooradian, A. D. (2010) · Drugs · doi:10.2165/11535410-000000000-00000 · Cited by 17
Ankle-brachial index in HIV infection
Olalla, J., Salas, D., Lima, J. D. L. T., del Arco, A., Prada, J. L., Crespo, F. M., Perea‐Milla, E., & García‐Alegría, J. (2009) · AIDS Research and Therapy · doi:10.1186/1742-6405-6-6 · Cited by 17
The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy*
Cooper, D., Cordery, D., Reiss, P., Henry, K., Nelson, M. R., O’Hearn, M., Reynes, J., Arastéh, K., Chung, J., Rowell, L., et al. (2010) · HIV Medicine · doi:10.1111/j.1468-1293.2010.00845.x · Cited by 17
Adverse Outcome Analyses of Observational Data: Assessing Cardiovascular Risk in HIV Disease
Triant, V. A., Josephson, F., Rochester, C. G., Althoff, K. N., Marcus, K. A., Munk, R., Cooper, C., D’Agostino, R. B., Costagliola, D. G., Sabin, C. A., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir829 · Cited by 17
Anti-HIV Agents: Current Status and Recent Trends
Geronikaki, A. A., Eleftheriou, P. T., & Poroikov, V. (2016) · Topics in medicinal chemistry · doi:10.1007/7355_2015_5001 · Cited by 17
Identification of Drug-Induced Myocardial Infarction-Related Protein Targets through the Prediction of Drug–Target Interactions and Analysis of Biological Processes
Ivanov, S. M., Lagunin, A. A., Pogodin, P. V., Filimonov, D. A., & Poroikov, V. (2014) · Chemical Research in Toxicology · doi:10.1021/tx500147d · Cited by 17
Growing old with HIV: The AIDS epidemic and an aging population
Myers, J. D. (2009) · JAAPA · doi:10.1097/01720610-200901000-00005 · Cited by 17

Authors: The DAD Study Group
Corresponding author: The DAD Study Group
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2007-04-26
Volume: 356
Issue: 17
Pages: 1723-1735
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa062744
OpenAlex: W1767400858
Cited by: 1,521
References: 26
Citations by year: 2026: 17 · 2025: 22 · 2024: 19 · 2023: 30 · 2022: 30 · 2021: 45 · 2020: 39 · 2019: 49 · 2018: 64 · 2017: 51 · 2016: 81 · 2015: 92 · 2014: 87 · 2013: 114 · 2012: 130
FWCI: 185.17
Type: journal article
Language: en
Open access: green
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Digital Access to Libraries (submittedVersion)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
UCL Discovery (University College London) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Columbia Academic Commons (Columbia University)
Funders: National Institute of Allergy and Infectious Diseases (U01AI046362, U01AI042170)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords: myocardial infarction, antiretroviral drugs, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, HIV infection, cardiovascular risk, dyslipidemia, serum lipids, drug exposure duration
MeSH terms: Adult, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Risk, HIV-1, HIV Infections, Incidence, Poisson Distribution, HIV Protease Inhibitors, Reverse Transcriptase Inhibitors, Observation, Anti-Retroviral Agents, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks